Analyses of Cytokinetics’ Clinical Data Provide Insights on ALS Care, Trial Design
Exploratory analysis of data collected in the FORTITUDE-ALS and VITALITY-ALS trials sponsored by Cytokinetics provide new insights to enhance…
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Exploratory analysis of data collected in the FORTITUDE-ALS and VITALITY-ALS trials sponsored by Cytokinetics provide new insights to enhance…
The majority of patients with amyotrophic lateral sclerosis (ALS) report wanting new treatments to stop their disease’s progression and so improve…
Sexuality and intimacy are important aspects of one’s life that are also affected by amyotrophic lateral sclerosis (ALS), according to…
Biogen has decided to exercise its option to acquire from Ionis Pharmaceuticals the exclusive rights to develop and commercialize…
A natural compound found in certain fruits and vegetables, called resveratrol, may help boost the ability of mesenchymal stem…
Cytokinetics has completed patient enrollment in its Phase 2 trial to evaluate the safety and potential of…
Amyotrophic lateral sclerosis (ALS) or frontotemporal lobar degeneration (FTLD) patients with the C9ORF72 mutation are at an unusually high risk…
Health conditions that may lead to a faster metabolism, or higher metabolic rate, may contribute to the development of…
Specific proteins analyzed in cerebral spinal fluid and blood samples may help to diagnose amyotrophic lateral sclerosis (ALS) and predict…
Inhibition of the SARM1 gene can prevent the degeneration of nerve cells in the central, ocular, and peripheral nervous system in…